PRFX stock touches 52-week low at $1.72 amid steep annual decline

Published 08/04/2025, 21:02
PRFX stock touches 52-week low at $1.72 amid steep annual decline

Painreform Ltd (PRFX) stock has plummeted to a 52-week low, trading at $1.72, as the company faces a challenging period marked by a significant downturn in its market valuation. With a market capitalization of just $1.56 million and an EBITDA of -$17.81 million, the company's financial health score on InvestingPro is rated as WEAK. Over the past year, PRFX has seen its stock value erode dramatically, with a 1-year change showing a staggering decrease of -95.12%. This sharp decline has alarmed investors and analysts alike, as the company grapples with market dynamics and internal challenges, including a concerning current ratio of 0.61 and negative free cash flow yield of -7%. According to InvestingPro analysis, while the RSI suggests the stock is in oversold territory, the company is quickly burning through cash. The 52-week low serves as a critical indicator of the stock's performance, reflecting investor sentiment and the company's ongoing efforts to stabilize and potentially reverse the downward trend. [Unlock 12 more exclusive InvestingPro Tips for PRFX]

In other recent news, PainReform Ltd. has announced a strategic shift towards the clean energy sector with the acquisition of DeepSolar, an AI-driven solar analytics platform. This acquisition is expected to generate significant revenue and enhance long-term shareholder value through DeepSolar's scalable SaaS platform. PainReform plans to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators. Financially, PainReform reported an increase in research and development expenses to approximately $11.7 million for the year ended December 31, 2024, up from $6.0 million the previous year, primarily due to clinical trial and manufacturing costs. General and administrative expenses decreased to $3.0 million from $3.6 million, attributed to lower insurance costs and share-based compensation expenses. The company experienced a net loss of approximately $14.6 million for the year, an increase from a net loss of $9.3 million in the prior year. A recent $0.9 million capital raise and the DeepSolar acquisition have bolstered shareholder equity, believed to now exceed Nasdaq's minimum requirement of $2.5 million. As of December 31, 2024, PainReform had a positive working capital of approximately $2.0 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.